Stankovic, B.; Stasuk, M.; Gasic, V.; Ristivojevic, B.; Grubisa, I.; Zukic, B.; Toplicanin, A.; Latinovic Bosnjak, O.; Smolovic, B.; Markovic, S.;
et al. Pharmacogenomic Pathways Underlying Variable Vedolizumab Response in Crohn’s Disease Patients: A Rare-Variant Analysis. Biomedicines 2026, 14, 203.
https://doi.org/10.3390/biomedicines14010203
AMA Style
Stankovic B, Stasuk M, Gasic V, Ristivojevic B, Grubisa I, Zukic B, Toplicanin A, Latinovic Bosnjak O, Smolovic B, Markovic S,
et al. Pharmacogenomic Pathways Underlying Variable Vedolizumab Response in Crohn’s Disease Patients: A Rare-Variant Analysis. Biomedicines. 2026; 14(1):203.
https://doi.org/10.3390/biomedicines14010203
Chicago/Turabian Style
Stankovic, Biljana, Mihajlo Stasuk, Vladimir Gasic, Bojan Ristivojevic, Ivana Grubisa, Branka Zukic, Aleksandar Toplicanin, Olgica Latinovic Bosnjak, Brigita Smolovic, Srdjan Markovic,
and et al. 2026. "Pharmacogenomic Pathways Underlying Variable Vedolizumab Response in Crohn’s Disease Patients: A Rare-Variant Analysis" Biomedicines 14, no. 1: 203.
https://doi.org/10.3390/biomedicines14010203
APA Style
Stankovic, B., Stasuk, M., Gasic, V., Ristivojevic, B., Grubisa, I., Zukic, B., Toplicanin, A., Latinovic Bosnjak, O., Smolovic, B., Markovic, S., Sokic Milutinovic, A., & Pavlovic, S.
(2026). Pharmacogenomic Pathways Underlying Variable Vedolizumab Response in Crohn’s Disease Patients: A Rare-Variant Analysis. Biomedicines, 14(1), 203.
https://doi.org/10.3390/biomedicines14010203
